Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 14/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7540327 | 0.88 | POLB (0.50) | POLBTSHRMAPK1PTGS1SLC22A12 | |
| SCHEMBL7534775 | 0.83 | CYP1A2 (0.42) | TSHRPTGS1TUBB1SLC22A12EPAS1 | |
| SCHEMBL6673879 | 0.83 | LMNA (0.55) | TSHRSLC22A12MEN1KMT2A | |
| SCHEMBL15867026 | 0.81 | ACLY (0.49) | SLC22A12EPAS1MEN1KMT2A | |
| SCHEMBL7535538 | 0.81 | PKM (0.56) | POLBTUBB1SLC22A12EPAS1 | |
| SCHEMBL7534412 | 0.79 | TUBB1 (0.60) | POLBTSHRMAPK1PTGS1TUBB1 | |
| SCHEMBL7540386 | 0.76 | VCAM1 (0.66) | POLBTSHRMAPK1PTGS1TUBB1 | |
| SCHEMBL7535465 | 0.75 | TUBB1 (0.50) | POLBTSHRMAPK1PTGS1TUBB1 | |
| Hydrochloric Acid SCHEMBL28228241 | 0.74 | ACLY (0.46) | SLC22A12EPAS1 | |
| SCHEMBL7537002 | 0.73 | SLC22A12 (0.43) | PTGS1SLC22A12EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | AMGEN INC. | 2002-01-31 | — | — | US | claimed |
| EP-1005453-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK, INC. (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1999010320-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK INC. (US) | 1999-03-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | CYP46A1, TGFB1, NR1H2 | POLB 638/4885TSHR 4093/4885MAPK1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.